Regeneron Pharmaceuticals (REGN) Leases (2013 - 2025)

Regeneron Pharmaceuticals' Leases history runs 12 years deep, the most recent figure standing at $576.7 million for Q4 2025.

• In Q4 2025, Leases fell 2.45% year-over-year to $576.7 million; the TTM figure through Dec 2025 stood at $576.7 million (down 2.45% YoY), while the FY2025 annual figure was $576.7 million, down 2.45% from the prior year.
• Leases was $576.7 million for Q4 2025 at Regeneron Pharmaceuticals, down from $591.2 million in the prior quarter.
• In the past five years, Leases ranged from a high of $631.3 million in Q4 2021 to a low of $576.7 million in Q4 2025.
• Historically, Leases has averaged $605.0 million across 5 years, with a median of $605.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Leases retreated 1.74% in 2022, then slipped 2.45% in 2025.
• A 5-year view of Leases shows it stood at $631.3 million in 2021, then slipped by 1.74% to $620.3 million in 2022, then slipped by 2.35% to $605.7 million in 2023, then retreated by 2.39% to $591.2 million in 2024, then retreated by 2.45% to $576.7 million in 2025.
• The last three Leases figures came in at $576.7 million (Q4 2025), $591.2 million (Q4 2024), and $605.7 million (Q4 2023), per Business Quant data.